FDG PET/CT in pancreatic and hepatobiliary carcinomas: Value to patient management and patient outcomes

Ujas Parikh, Charles Marcus, Rutuparna Sarangi, Mehdi Taghipour, Rathan M. Subramaniam

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Fludeoxyglucose F 18 (18F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of 18F-FDG PET/CT in initial staging and patient prognosis. There is evidence for 18F-FDG PET and 18F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. 18F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of 18F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.

Original languageEnglish (US)
Pages (from-to)327-343
Number of pages17
JournalPET Clinics
Volume10
Issue number3
DOIs
StatePublished - Jan 1 2015

Fingerprint

prognosis
Fluorodeoxyglucose F18
cancer
metastasis
liver
Neoplasm Metastasis
Gallbladder Neoplasms
Cholangiocarcinoma
Liver
Pancreatic Neoplasms
Pancreatic Carcinoma
Hepatocellular Carcinoma
Survival
Neoplasms

Keywords

  • <sup>18</sup>F-FDG PET/CT
  • Hepatocellular carcinoma
  • Pancreatic cancer

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

FDG PET/CT in pancreatic and hepatobiliary carcinomas : Value to patient management and patient outcomes. / Parikh, Ujas; Marcus, Charles; Sarangi, Rutuparna; Taghipour, Mehdi; Subramaniam, Rathan M.

In: PET Clinics, Vol. 10, No. 3, 01.01.2015, p. 327-343.

Research output: Contribution to journalArticle

Parikh, Ujas ; Marcus, Charles ; Sarangi, Rutuparna ; Taghipour, Mehdi ; Subramaniam, Rathan M. / FDG PET/CT in pancreatic and hepatobiliary carcinomas : Value to patient management and patient outcomes. In: PET Clinics. 2015 ; Vol. 10, No. 3. pp. 327-343.
@article{597c8da87e134615b33236326ee76e8e,
title = "FDG PET/CT in pancreatic and hepatobiliary carcinomas: Value to patient management and patient outcomes",
abstract = "Fludeoxyglucose F 18 (18F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of 18F-FDG PET/CT in initial staging and patient prognosis. There is evidence for 18F-FDG PET and 18F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. 18F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of 18F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.",
keywords = "<sup>18</sup>F-FDG PET/CT, Hepatocellular carcinoma, Pancreatic cancer",
author = "Ujas Parikh and Charles Marcus and Rutuparna Sarangi and Mehdi Taghipour and Subramaniam, {Rathan M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.cpet.2015.03.001",
language = "English (US)",
volume = "10",
pages = "327--343",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - FDG PET/CT in pancreatic and hepatobiliary carcinomas

T2 - Value to patient management and patient outcomes

AU - Parikh, Ujas

AU - Marcus, Charles

AU - Sarangi, Rutuparna

AU - Taghipour, Mehdi

AU - Subramaniam, Rathan M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Fludeoxyglucose F 18 (18F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of 18F-FDG PET/CT in initial staging and patient prognosis. There is evidence for 18F-FDG PET and 18F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. 18F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of 18F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.

AB - Fludeoxyglucose F 18 (18F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of 18F-FDG PET/CT in initial staging and patient prognosis. There is evidence for 18F-FDG PET and 18F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. 18F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of 18F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.

KW - <sup>18</sup>F-FDG PET/CT

KW - Hepatocellular carcinoma

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84931957361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931957361&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2015.03.001

DO - 10.1016/j.cpet.2015.03.001

M3 - Article

C2 - 26099670

AN - SCOPUS:84931957361

VL - 10

SP - 327

EP - 343

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

IS - 3

ER -